Combipatch®
(estradiol/norethindrone acetate transdermal system)
0.05/0.14, 0.05/0.25 mg per day

Sample Request Form

Fax to 1-877-540-6497

Noven Therapeutics, LLC.

Reference# WEB

Practitioner's Last Name (required) **First Name** (required) **Professional Designation** (required)

State License Number (required) **Expiration Date** (required)

TDDD License Number/Expiration Date (required for Ohio Healthcare Providers only)

Office Address (required-PO boxes are not accepted) **City** (required) **State** (required) **Zip** (required)

Phone Number Fax Number Email

CombiPatch® (estradiol/norethindrone acetate transdermal system) Samples

Please check the box for each sample dose requested. You will receive 4 sample boxes per dose (one sample box contains 2 patches).

- ☐ CombiPatch 0.05/0.14 mg/day
- ☐ CombiPatch 0.05/0.25 mg/day

NOTE

While supplies last. Only one form can be submitted per month.

This form must be filled out completely before your sample request can be processed.

If eligible, you should expect samples to arrive within 2 weeks from the date your fax request is received. If you have any questions regarding your request, please call 1-877-540-6498 (M-F 8am-5pm EST).

Practitioner Certification

I, a licensed practitioner, certify that all the information on this form is correct and that I am licensed with the appropriate state authorities and eligible under state law to request, receive, prescribe, and dispense the above samples. I have requested the packaged quantities shown on this document for the product indicated. I understand and agree that the samples are subject to the requirements of the Prescription Drug Marketing Act and cannot be sold, traded, bartered, billed, returned for credit, or utilized to seek reimbursement.

Date: / /

Practitioner's Signature (Request cannot be fulfilled unless this form is signed and dated in ink. Must be original, no signature stamps accepted.)

INDICATION

CombiPatch® (estradiol/norethindrone acetate transdermal system) is indicated for women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause, and moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. CombiPatch is also indicated for treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.

IMPORTANT SAFETY INFORMATION

Estrogens and progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive pulmonary emboli (PE), and deep vein thrombosis (DVT) in postmenopausal women.

The Women's Health Initiative Memory Study (WHIMS), reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older.

Please see additional Boxed WARNING and Important Safety Information on next page.

CBP-2705-16 06/18

IMPORTANT SAFETY INFORMATION (cont'd)

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.

In the absence of comparable data, these risks should be assumed to be similar for all doses and dosage forms of estrogen and progestin containing products. Because of these risks, estrogens with progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

CombiPatch should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, PE, arterial thromboembolic disease, or history of these conditions; liver dysfunction or disease; known anaphylactic reaction or angioedema or hypersensitivity to CombiPatch; known protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders or known or suspected pregnancy.

Estrogen increases the risk of gallbladder disease. Discontinue estrogen plus progestin if severe hypercalcemia, vision abnormalities, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy.

In clinical trials with CombiPatch, the most common side effects were breast pain, dysmenorrhea, and headache.

These are not all the side effects of CombiPatch.

Please visit www.combipatch.com for the Full Prescribing Information, including Boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

noven
THERAPEUTICS, LLC

CombiPatch® is a registered trademark of Noven Therapeutics, LLC.

© 2018 Noven Therapeutics, LLC. All rights reserved. For U.S. Audience Only.

CBP-2705-16 06/18